EPS for Clearside Biomedical, Inc. (CLSD) Expected At $-0.37

Analysts expect Clearside Biomedical, Inc. (NASDAQ:CLSD) to report $-0.37 EPS on August, 14.They anticipate $0.28 EPS change or 43.08 % from last quarter’s $-0.65 EPS. After having $-0.45 EPS previously, Clearside Biomedical, Inc.’s analysts see -17.78 % EPS growth. The stock increased 28.00% or $0.28 during the last trading session, reaching $1.28. About 1.92M shares traded or 442.50% up from the average. Clearside Biomedical, Inc. (NASDAQ:CLSD) has declined 87.13% since August 9, 2018 and is downtrending. It has underperformed by 87.13% the S&P500.

Clearside Biomedical, Inc., a late-stage clinical biopharmaceutical company, develops first-in-class drug therapies to treat blinding diseases of the eye. The company has market cap of $60.39 million. It is developing suprachoroidal injection of CLS-TA, a proprietary preservative-free formulation of the corticosteroid triamcinolone acetonide, which is in Phase III clinical trial for the treatment of macular edema associated with non-infectious uveitis; suprachoroidal injection of CLS-TA and a concomitant intravitreal injection of Eylea, an inhibitor of vascular endothelial growth factor that is in Phase III clinical trial to treat macular edema associated with retinal vein occlusion ; and suprachoroidal injection of CLS-TA alone or together with intravitreal injection of Eylea that is in phase I/II clinical trial for diabetic macular edema (DME). It currently has negative earnings. The company's pre-clinical development program for axitinib for the treatment of wet age-related macular degeneration (wet AMD).

More notable recent Clearside Biomedical, Inc. (NASDAQ:CLSD) news were published by: Fool.com which released: “Clearside Biomedical Stock Down 26%: The “Positive” Data That Wasn’t – The Motley Fool” on May 31, 2018, also Nasdaq.com with their article: “Clearside Biomedical Announces Second Quarter 2019 Financial Results and Provides Corporate Update – Nasdaq” published on August 07, 2019, Seekingalpha.com published: “Clearside Biomedical’s (CLSD) CEO George Lasezkay on Q2 2019 Results – Earnings Call Transcript – Seeking Alpha” on August 08, 2019. More interesting news about Clearside Biomedical, Inc. (NASDAQ:CLSD) were released by: Seekingalpha.com and their article: “Wall Street Sunday Breakfast: Stocks To Watch – Seeking Alpha” published on May 19, 2019 as well as Nasdaq.com‘s news article titled: “Clearside Biomedical Announces Multiple Oral Presentations to be Given at the American Society of Retinal Specialists (ASRS) Annual Meeting – Nasdaq” with publication date: July 18, 2019.

Clearside Biomedical, Inc. (NASDAQ:CLSD) Ratings Chart

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.